Login to Your Account



Given due weight: Result in Alkermes bid satisfies, to 'Enlighten' more later

By Randy Osborne
Staff Writer

Friday, June 30, 2017

Efficacy against acute exacerbations of schizophrenia looks strong in top-line phase III data from the four-week Enlighten-1 trial with Alkermes plc's ALKS-3831, but the world won't know until next year about the weight gain and metabolic aspects investigated by a six-month experiment called Enlighten-2.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription